Display options
Share it on

PPAR Res. 2015;2015:927057. doi: 10.1155/2015/927057. Epub 2015 Oct 29.

PPARα Is Required for PPARδ Action in Regulation of Body Weight and Hepatic Steatosis in Mice.

PPAR research

Wojciech G Garbacz, Jeffrey T J Huang, Larry G Higgins, Walter Wahli, Colin N A Palmer

Affiliations

  1. Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK.
  2. Center for Integrative Genomics, University of Lausanne, Le Genopode, 1015 Lausanne, Switzerland ; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232 ; INRA ToxAlim, UMR 1331, Chemin de Tournefeuille, 31300 Toulouse Cedex, France.

PMID: 26604919 PMCID: PMC4641930 DOI: 10.1155/2015/927057

Abstract

Peroxisome proliferator activated receptors alpha (PPARα) and delta (PPARδ) belong to the nuclear receptor superfamily. PPARα is a target of well established lipid-lowering drugs. PPARδ (also known as PPARβ/δ) has been investigated as a promising antidiabetic drug target; however, the evidence in the literature on PPARδ effect on hepatic lipid metabolism is inconsistent. Mice conditionally expressing human PPARδ demonstrated pronounced weight loss and promoted hepatic steatosis when treated with GW501516 (PPARδ-agonist) when compared to wild type mice. This effect was completely absent in mice with either a dominant negative form of PPARδ or deletion of the DNA binding domain of PPARδ. This confirmed the absolute requirement for PPARδ in the physiological actions of GW501516 and confirmed the potential utility against the human form of this receptor. Surprisingly the genetic deletion of PPARα also abrogated the effect of GW501516 in terms of both weight loss and hepatic lipid accumulation. Also the levels of the PPARα endogenous agonist 16:0/18:1-GPC were shown to be modulated by PPARδ in wild type mice. Our results show that both PPARδ and PPARα receptors are essential for GW501516-driven adipose tissue reduction and subsequently hepatic steatosis, with PPARα working downstream of PPARδ.

References

  1. Cell. 2009 Aug 7;138(3):476-88 - PubMed
  2. J Biol Chem. 2003 Jan 3;278(1):498-505 - PubMed
  3. Comp Hepatol. 2012 Apr 23;11(1):1 - PubMed
  4. Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15924-9 - PubMed
  5. J Cell Biol. 2001 Aug 20;154(4):799-814 - PubMed
  6. J Lipid Res. 2006 Apr;47(4):804-14 - PubMed
  7. J Cell Sci. 1996 Nov;109 ( Pt 11):2619-25 - PubMed
  8. Diabetes. 2008 Feb;57(2):332-9 - PubMed
  9. Mol Cell Biol. 1995 Jun;15(6):3012-22 - PubMed
  10. Gut. 2007 Dec;56(12):1760-9 - PubMed
  11. Nature. 1990 Oct 18;347(6294):645-50 - PubMed
  12. Mol Pharmacol. 1998 Jan;53(1):14-22 - PubMed
  13. PLoS One. 2011 Jan 19;6(1):e16344 - PubMed
  14. Hepatology. 2008 Aug;48(2):432-41 - PubMed
  15. J Lipid Res. 2005 Mar;46(3):582-8 - PubMed
  16. Biochim Biophys Acta. 2007 Oct;1771(10):1263-70 - PubMed
  17. Atherosclerosis. 2005 Jul;181(1):29-37 - PubMed
  18. Clin Sci (Lond). 2008 Apr;114(8):547-52 - PubMed
  19. Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7473-8 - PubMed
  20. Endocrinology. 2011 May;152(5):1848-59 - PubMed
  21. Br J Pharmacol. 2011 Sep;164(1):68-82 - PubMed
  22. J Lipid Res. 2006 Feb;47(2):329-40 - PubMed
  23. J Biol Chem. 1995 Jul 7;270(27):16114-21 - PubMed
  24. Cell. 2008 Aug 8;134(3):405-15 - PubMed
  25. J Clin Invest. 2006 Mar;116(3):590-7 - PubMed
  26. World J Gastroenterol. 2008 Jan 14;14(2):193-9 - PubMed
  27. J Biol Chem. 2012 Mar 9;287(11):8444-56 - PubMed
  28. J Clin Invest. 1999 Jun;103(11):1489-98 - PubMed
  29. Eur J Endocrinol. 2009 Nov;161(5):705-13 - PubMed
  30. Biochim Biophys Acta. 2007 Sep;1771(9):1125-31 - PubMed
  31. Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5306-11 - PubMed
  32. PPAR Res. 2007;2007:95974 - PubMed
  33. PPAR Res. 2012;2012:216817 - PubMed
  34. Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3444-9 - PubMed
  35. Am J Med Genet B Neuropsychiatr Genet. 2008 Jul 5;147B(5):637-44 - PubMed
  36. Curr Opin Lipidol. 2009 Aug;20(4):333-6 - PubMed
  37. Biochimie. 2005 Jan;87(1):15-20 - PubMed
  38. Diabetes. 2009 Mar;58(3):579-89 - PubMed
  39. Comp Biochem Physiol A Mol Integr Physiol. 2012 Sep;163(1):152-60 - PubMed
  40. Diabetes Obes Metab. 2010 Mar;12(3):234-45 - PubMed
  41. Cell. 1992 Mar 6;68(5):879-87 - PubMed
  42. J Rheumatol. 2012 Oct;39(10 ):2032-40 - PubMed
  43. Physiol Genomics. 2009 May 13;37(3):187-98 - PubMed
  44. Mol Nutr Food Res. 2012 Jun;56(6):878-88 - PubMed
  45. Crit Rev Eukaryot Gene Expr. 2008;18(3):207-50 - PubMed
  46. Mol Cell Endocrinol. 2010 Apr 29;318(1-2):61-8 - PubMed
  47. J Biol Chem. 1957 May;226(1):497-509 - PubMed
  48. Drug Metab Dispos. 2011 Dec;39(12):2395-402 - PubMed
  49. Drug Discov Ther. 2011 Aug;5(4):176-80 - PubMed
  50. PLoS One. 2009 Sep 16;4(9):e7046 - PubMed
  51. Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4271-6 - PubMed
  52. PLoS One. 2010 Mar 16;5(3):e9701 - PubMed
  53. PLoS One. 2010 Oct 13;5(10):e13318 - PubMed
  54. Biochem Biophys Res Commun. 2008 Jul 4;371(3):456-61 - PubMed
  55. J Biol Chem. 2012 Jul 20;287(30):25038-48 - PubMed
  56. J Anim Physiol Anim Nutr (Berl). 2008 Jun;92(3):272-83 - PubMed
  57. J Biol Chem. 2011 Jan 14;286(2):1237-47 - PubMed
  58. Diabetologia. 2011 Jan;54(1):135-45 - PubMed
  59. Nutr Metab Cardiovasc Dis. 2009 May;19(4):291-302 - PubMed
  60. Biochim Biophys Acta. 2011 Aug;1812(8):1007-22 - PubMed
  61. FEBS J. 2006 Apr;273(8):1669-80 - PubMed

Publication Types